Respiratory · Clinical trials
Chronic Rhinosinusitis with Nasal Polyps Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About chronic rhinosinusitis with nasal polyps — and why its trials are hard
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type-2 inflammatory disease of the sinonasal mucosa marked by bilateral polyps, nasal obstruction, loss of smell, rhinorrhoea and facial pressure persisting beyond twelve weeks. It frequently coexists with asthma and aspirin-exacerbated respiratory disease, and eosinophilic inflammation driven by IL-4, IL-5 and IL-13 underlies recurrence after surgery. Standard care is intranasal corticosteroids, saline irrigation, short oral steroid courses and endoscopic sinus surgery, but relapse is common. The therapeutic landscape shifted decisively with monoclonal antibodies: dupilumab (anti-IL-4Ra) became the first biologic approved in 2019, followed by omalizumab (anti-IgE) and mepolizumab (anti-IL-5). These agents reduce polyp burden, improve smell and congestion, and cut the need for surgery and systemic steroids. Trials consistently use co-primary endpoints of nasal polyp score and nasal congestion. Biologic selection, cost and long-term durability remain active questions, and head-to-head comparative data are limited.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Dupilumab (Dupixent) | 2019 | Add-on to intranasal corticosteroids in adults with inadequately controlled severe CRSwNP | LIBERTY NP SINUS-24 and SINUS-52 (phase 3, Lancet 2019) | Co-primary: change in nasal polyp score (NPS) and nasal congestion/obstruction score at week 24 | NPS improved by roughly 2 points versus placebo (approx -1.9 SINUS-24; both co-primaries and loss-of-smell markedly improved, p<0.0001) |
| Omalizumab (Xolair) | 2020 | Add-on to intranasal mometasone in adults with CRSwNP | POLYP 1 and POLYP 2 (phase 3) | Co-primary: change in nasal polyp score and nasal congestion score at week 24 | Significant reductions in both NPS (approx -1.1 to -1.2 vs placebo) and nasal congestion score (p<0.001) |
| Mepolizumab (Nucala) | 2021 | Add-on maintenance for adults with severe CRSwNP | SYNAPSE (phase 3) | Co-primary: change in total endoscopic nasal polyp score at week 52 and nasal obstruction VAS over weeks 49-52 | Statistically significant improvement in polyp score and nasal obstruction versus placebo; reduced need for surgery (p<0.001) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in chronic rhinosinusitis with nasal polyps development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Oral corticosteroid-sparing conventional agents (e.g., methotrexate, doxycycline for maintenance) — Small RCTs / observational studies (no pivotal registration trial) | No durable, robustly reproduced reduction in polyp recurrence in adequately powered trials (unverified as formal pivotal failures) | Underpowered studies, heterogeneous endpoints and lack of type-2 targeting; specific trial-level failure details (unverified) |
Choosing the right endpoint
Primary endpoints that matter in chronic rhinosinusitis with nasal polyps trials
- Nasal Polyp Score (NPS) — Endoscopic 0-8 bilateral grading; primary structural efficacy measure in all pivotal biologic trials
- Nasal Congestion/Obstruction Score — Patient-reported daily symptom score; co-primary endpoint alongside NPS
- University of Pennsylvania Smell Identification Test (UPSIT) — Quantifies olfactory recovery, a key patient-valued outcome
- SNOT-22 — Sino-Nasal Outcome Test measuring disease-specific quality of life
- Need for systemic steroids or sinus surgery — Clinically meaningful secondary endpoint reflecting disease control
How iNGENū runs chronic rhinosinusitis with nasal polyps trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Chronic Rhinosinusitis with Nasal Polyps clinical trials — FAQs
Which biologic was approved first for CRSwNP?
Do biologics replace sinus surgery?
What are the standard trial endpoints?
Ready to discuss your chronic rhinosinusitis with nasal polyps trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal